Intravenous Immunoglobulin Therapy for Autoantibody-Positive Cerebellar Ataxia

Nanri, Kazunori; Okita, Mitsunori; Takeguchi, Masafumi; Taguchi, Takeshi; Ishiko, Tomoko; Saito, Hirohiko; Otsuka, Takao; Mitoma, Hiroshi; Koizumi, Kiyoshi

doi:10.2169/internalmedicine.48.1802

Cited by 68 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, Nanri et al described a clear improvement in ICARS in two patients with anti-GAD ataxia using immunoglobulin. Additionally, steroids and immunosuppressive agents might also be used 5 . This short report and analyses of previous data suggest that testing for GAD antibodies may be indicated in patients with sporadic cerebellar ataxia, particularly when type 1 diabetes is present.…”

Section: Discussionmentioning

confidence: 99%

Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy

Pedroso

Braga‐Neto

Dutra

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy

Pedroso

Braga‐Neto

Dutra

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

“…A whole-body computed tomographic scan, fecal occult blood test, and tumor marker test were performed, and patients with cancer were excluded. This study also included cases that had been previously reported (1,2).…”

Section: Figure We Enrolled 58 Idiopathic Cerebellar Ataxia Patientsmentioning

confidence: 99%

“…Autoimmune cerebellar ataxias, including anti-glutamic acid decarboxylase (GAD) antibody-positive cerebellar ataxia (1,2), gluten ataxia (3,4), and Hashimoto's encephalopathy (5,6), were recently reported to be treatable.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Autoantibodies and the Efficacy of Immunotherapy for Autoimmune Cerebellar Ataxia

et al. 2016

Self Cite

View full text Add to dashboard Cite

Objective Autoimmune cerebellar ataxias were recently reported to be treatable. However, the proportion of patients with cortical cerebellar atrophy of unknown etiology with autoimmune-associated cerebellar ataxia and the actual effectiveness of immunotherapy in these diseases remain unknown. Methods We measured the level of autoantibodies (including anti-gliadin antibody, anti-glutamic acid decarboxylase (GAD) antibody, and anti-thyroid antibody) in 58 Japanese patients with cerebellar ataxia, excluding those with multiple system atrophy, hereditary spinocerebellar ataxia, cancer, or those who were receiving phenytoin, and the efficacy of immunotherapy was assessed. Results Thirty-one of 58 (53%) patients were positive for anti-GAD antibody, anti-gliadin antibody, or antithyroid antibody. Seven of the 12 anti-gliadin antibody-positive patients, three of the four anti-GAD antibody-positive patients, and three of the six anti-thyroid antibody-positive patients responded well to immunotherapy, indicating that 59% of patients with ataxia-associated antibody-positive cerebellar ataxia undergoing immunotherapy responded well. Conclusion Some patients with cerebellar ataxia have autoimmune conditions and diagnosing autoimmune cerebellar ataxia is therefore an important component in the care of patients with this disease entity.

show abstract

“…In pilot studies, IVIG appeared to stabilize cognitive functioning in individuals with Alzheimer's disease (AD) [37,38], and a phase III IVIG trial with AD patients is in progress. IVIG administration to patients with DLB and MSA has also been reported [39,40] but little is known of its effects on α-synuclein. In our previous study [34], as shown by western blots of reducing/denaturing gels, IVIG preparations did not prevent short-term (four-day) development of α-synuclein soluble oligomers, although alterations were seen in the distribution of the oligomer bands.…”

Section: Introductionmentioning

confidence: 99%

Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity

Smith

Klaver

Coffey

et al. 2012

International Immunopharmacology

View full text Add to dashboard Cite

Intravenous Immunoglobulin Therapy for Autoantibody-Positive Cerebellar Ataxia

Cited by 68 publications

References 34 publications

Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy

Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy

Prevalence of Autoantibodies and the Efficacy of Immunotherapy for Autoimmune Cerebellar Ataxia

Effects of intravenous immunoglobulin on alpha synuclein aggregation and neurotoxicity

Contact Info

Product

Resources

About